Synaptic Vesicle Glycoprotein 2A Ligands in the Treatment of Epilepsy and Beyond.
Synaptic Vesicle Glycoprotein 2A Ligands in the Treatment of Epilepsy and Beyond.
复制标题
DOI：
10.1007/s40263-016-0384-x
复制
发表时间：
2016-11
期刊：
影响因子：
6
通讯作者：
Klitgaard, Henrik
中科院分区：
文献类型：
--
作者：
Loescher, Wolfgang;Gillard, Michel;Sands, Zara A.;Kaminski, Rafal M.;Klitgaard, Henrik
突触囊泡糖蛋白SV2A属于转运蛋白的主要促进剂超家族（MFS），是突触囊泡膜的一个组成部分。SV2A已被证明参与囊泡运输和胞外分泌，这是神经传递的关键过程。抗癫痫药物左乙拉西坦是第一个靶向SV2A的配体，在各种临床前模型中显示出广谱的抗癫痫活性。包括遗传学和蛋白表达变化在内的多项临床前和临床证据支持SV2A在癫痫病理生理中的重要作用。虽然SV2A配体结合的功能后果尚未完全阐明，但研究表明，随后的SV2A构象变化可能有助于癫痫发作保护。相反，最近发现的负SV2A调节剂，如UCB0255，在临床前模型中抵消了左乙拉西坦的抗癫痫作用，并显示出促进认知的特性。更广泛地说，SV2A功能障碍也可能涉及阿尔茨海默病和其他类型的认知障碍，提示左乙拉西坦及其同类药物的潜在新疗法。此外，新出现的数据表明，另外两种SV2亚型（SV2B和SV2C）可能在癫痫以及其他神经退行性疾病的发病机制中发挥重要作用。利用最近开发的SV2A正电子发射断层扫描配体将加强和加强SV2A是一个可药物靶点的药理学证据，并将更好地了解其在癫痫和其他神经系统疾病中的作用，有助于进一步确定SV2A调节的全部治疗潜力。
The synaptic vesicle glycoprotein SV2A belongs to the major facilitator superfamily (MFS) of transporters and is an integral constituent of synaptic vesicle membranes. SV2A has been demonstrated to be involved in vesicle trafficking and exocytosis, processes crucial for neurotransmission. The anti-seizure drug levetiracetam was the first ligand to target SV2A and displays a broad spectrum of anti-seizure activity in various preclinical models. Several lines of preclinical and clinical evidence, including genetics and protein expression changes, support an important role of SV2A in epilepsy pathophysiology. While the functional consequences of SV2A ligand binding are not fully elucidated, studies suggest that subsequent SV2A conformational changes may contribute to seizure protection. Conversely, the recently discovered negative SV2A modulators, such as UCB0255, counteract the anti-seizure effect of levetiracetam and display procognitive properties in preclinical models. More broadly, dysfunction of SV2A may also be involved in Alzheimer’s disease and other types of cognitive impairment, suggesting potential novel therapies for levetiracetam and its congeners. Furthermore, emerging data indicate that there may be important roles for two other SV2 isoforms (SV2B and SV2C) in the pathogenesis of epilepsy, as well as other neurodegenerative diseases. Utilization of recently developed SV2A positron emission tomography ligands will strengthen and reinforce the pharmacological evidence that SV2A is a druggable target, and will provide a better understanding of its role in epilepsy and other neurological diseases, aiding in further defining the full therapeutic potential of SV2A modulation.
登录
查看更多内容
影响因子：
56.9
作者：
BAJJALIEH, SM;PETERSON, K;SCHELLER, RH
通讯作者：
SCHELLER, RH
影响因子：
2.2
作者：
Barton, ME;Klein, BD;White, HS
通讯作者：
White, HS
影响因子：
16.2
作者：
Bakker A;Krauss GL;Albert MS;Speck CL;Jones LR;Stark CE;Yassa MA;Bassett SS;Shelton AL;Gallagher M
通讯作者：
Gallagher M
影响因子：
2.2
作者：
Banerjee, Poonam Nina;Filippi, David;Hauser, W. Allen
通讯作者：
Hauser, W. Allen
影响因子：
3.1
作者：
Bretin, F.;Bahri, M. A.;Salmon, E.
通讯作者：
Salmon, E.